Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody-armored Dendritic Cell Injection in Solid Tumors
NCT07479667Phase 1Recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in solid tumor, sponsored by Shanghai Cell Therapy Group. Primary endpoints: Maximum Tolerated Dose and Adverse Events. Started Feb 2026; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07479667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479667.